Development of inhibitors in women with mild haemophilia A and concurrent treatment with immune tolerance therapy and emicizumab.

The development of inhibitors is a rare but severe complication for people living with haemophilia. This patient benefited from the concurrent use of ITI and emicizumab with reasonable bleeding control and inhibitor eradication, making it the first reported case of concurrent ITI and emicizumab in the rare population of haemophilia A carrier with inhibitor. Her father and elder brother have severe haemophilia A and two sisters who are known heterozygous carriers of haemophilia A mutation. [Extracted from the article]